These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 32709942)

  • 21. Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries.
    Fudim M; Zhong L; Patel KV; Khera R; Abdelmalek MF; Diehl AM; McGarrah RW; Molinger J; Moylan CA; Rao VN; Wegermann K; Neeland IJ; Halm EA; Das SR; Pandey A
    J Am Heart Assoc; 2021 Nov; 10(22):e021654. PubMed ID: 34755544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes.
    Ciardullo S; Perseghin G
    Metabolism; 2021 Aug; 121():154752. PubMed ID: 33716004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Non-Alcoholic Fatty Liver Disease With in-Hospital Outcomes in Primary Heart Failure Hospitalizations With Reduced or Preserved Ejection Fraction.
    Minhas AMK; Bhopalwala HM; Dewaswala N; Salah HM; Khan MS; Shahid I; Biegus J; Lopes RD; Pandey A; Fudim M
    Curr Probl Cardiol; 2023 Aug; 48(8):101199. PubMed ID: 35405161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients.
    Singh A; Le P; Peerzada MM; Lopez R; Alkhouri N
    J Clin Gastroenterol; 2018 Mar; 52(3):268-272. PubMed ID: 28787358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.
    Le MH; Devaki P; Ha NB; Jun DW; Te HS; Cheung RC; Nguyen MH
    PLoS One; 2017; 12(3):e0173499. PubMed ID: 28346543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Metabolites Are Associated With HFpEF in Biopsy-Proven Nonalcoholic Fatty Liver Disease.
    Wegermann K; Fudim M; Henao R; Howe CF; McGarrah R; Guy C; Abdelmalek MF; Diehl AM; Moylan CA
    J Am Heart Assoc; 2023 Jul; 12(14):e029873. PubMed ID: 37421270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
    J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver fibrosis scores and atrial fibrillation incidence in heart failure with preserved ejection fraction.
    Liu X; Chen W; Shao W; Jiang Y; Cao Z; He W; Wu M; Chen Z; Ma J; Chen Y; Yu P; Zhang Y; Wang J
    ESC Heart Fail; 2022 Dec; 9(6):3985-3994. PubMed ID: 35996808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients.
    Yuan XX; Zhu HJ; Pan H; Chen S; Liu ZY; Li Y; Wang LJ; Lu L; Yang HB; Gong FY
    World J Gastroenterol; 2019 Apr; 25(14):1741-1752. PubMed ID: 31011258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
    Chen K; Sng WK; Quah JH; Liu J; Chong BY; Lee HK; Wang XF; Tan NC; Chang PE; Tan HC; Bee YM; Goh GBB
    PLoS One; 2020; 15(8):e0236977. PubMed ID: 32822391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and Profile of Fibrosis in Diabetic Patients with Non-alcoholic Fatty Liver Disease and the Associated Factors.
    Prasetya IB; Hasan I; Wisnu W; Rumende CM
    Acta Med Indones; 2017 Apr; 49(2):91-98. PubMed ID: 28790222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease.
    Semmler G; Bachmayer S; Wernly S; Wernly B; Niederseer D; Huber-Schönauer U; Stickel F; Aigner E; Datz C
    PLoS One; 2020; 15(12):e0244514. PubMed ID: 33382757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depression is associated with non-alcoholic fatty liver disease among adults in the United States.
    Kim D; Yoo ER; Li AA; Tighe SP; Cholankeril G; Harrison SA; Ahmed A
    Aliment Pharmacol Ther; 2019 Sep; 50(5):590-598. PubMed ID: 31328300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
    Julián MT; Pera G; Soldevila B; Caballería L; Julve J; Puig-Jové C; Morillas R; Torán P; Expósito C; Puig-Domingo M; Castelblanco E; Franch-Nadal J; Cusi K; Mauricio D; Alonso N
    Eur J Endocrinol; 2021 Apr; 184(4):587-596. PubMed ID: 33606661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
    Angulo P; Kleiner DE; Dam-Larsen S; Adams LA; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Keach JC; Lafferty HD; Stahler A; Haflidadottir S; Bendtsen F
    Gastroenterology; 2015 Aug; 149(2):389-97.e10. PubMed ID: 25935633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction.
    Yoshihisa A; Sato Y; Yokokawa T; Sato T; Suzuki S; Oikawa M; Kobayashi A; Yamaki T; Kunii H; Nakazato K; Saitoh SI; Takeishi Y
    ESC Heart Fail; 2018 Apr; 5(2):262-270. PubMed ID: 28967709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study.
    Nickel F; Tapking C; Benner L; Sollors J; Billeter AT; Kenngott HG; Bokhary L; Schmid M; von Frankenberg M; Fischer L; Mueller S; Müller-Stich BP
    Obes Surg; 2018 May; 28(5):1342-1350. PubMed ID: 29119336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.